BL 1826
Alternative Names: Nicotine sublingual aerosol sprayLatest Information Update: 03 Dec 2002
At a glance
- Originator Bioglan Pharma [CEASED]
- Class Nicotine replacement therapy
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Smoking withdrawal
Most Recent Events
- 03 Dec 2002 Discontinued - Phase-II for Smoking withdrawal in USA (Sublingual)
- 21 Aug 2001 Phase-II clinical trials for Smoking withdrawal in USA (Sublingual)